JPRN-jRCT2080221166未知3 期
Phase 3 study on combinational therapy of SMP-508 with metformin in patients with type 2 diabetes mellitus
试验速览
- 阶段
- 3 期
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients with type 2 diabetes mellitus who meet the following requirements
- •-Patients who have been on a fixed regimen of diet and exercise therapies
- •-Patients who have been taking metformin continuously at a fixed dose
- •-Patients whose HbA1C level is 6.5% <= HbA1C <= 9.0% and is stable over 4 weeks
- •-Patients aged 20 or older
- •-Outpatients
排除标准
- •-Patients with history of lactic acidosis
- •-Patients with hepatic dysfunction
- •-Patients with renal dysfunction
- •-Patients with cardiac diseases
- •-Patients with severe hypertension
研究者
相似试验
未知
3 期
Phase 3 study on combinational therapy of SMP-508 with pioglitazone in patients with type 2 diabetes mellitusType 2 diabetes mellitus patients whose blood glucose levels are not adequately controlled by pioglitazone in addition to diet and exercise therapiesJPRN-jRCT2080221168Dainippon Sumitomo Pharma Co., Ltd.120
未知
3 期
ong-term study on combinational therapy of SMP-508 with dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitusJPRN-jRCT2080221738Sumitomo Dainippon Pharma Co.,Ltd.80
未知
3 期
ong-term study on combinational therapy of SMP-508 with pioglitazone in patients with type 2 diabetes mellitusType 2 diabetes mellitus whose blood glucose levels are not adequately controlled by pioglitazone in addition to diet and exercise therapiesJPRN-jRCT2080221169Dainippon Sumitomo Pharma Co., Ltd.120
未知
3 期
ong-term study on combinational therapy of SMP-508 with metformin in patients with type 2 diabetes mellitusType 2 diabetes mellitus whose blood glucose levels are not adequately controlled by metformin in addition to diet and exercise therapiesJPRN-jRCT2080221167Dainippon Sumitomo Pharma Co., Ltd.120
未知
3 期
Phase III study on dose response of SMP-508 monotherapy in patients with type 2 diabetes mellitusJPRN-jRCT2080220511Dainippon Sumitomo Pharma Co., Ltd.